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Abstract 
Mortality from human papillomavirus (HPV) mediated squamous carcinoma of the uterine cervix has dramatically 
decreased in recent decades as a result of broad scale population screening for early detection of cervical cancer precursors. 
Concomitantly, deaths associated with HPV related carcinomas of the anus have oppositely trended upward. At this time, 
there are no national guidelines for anal screening. We herein report our experience with establishing an anal cytology 
screening program for HIV infected patients in a small city. The HIV positive population studied is unique in that 75% of 
patients had undetectable viral loads by PCR with average CD4+ cell/uL counts of 550. In addition 40% are adult females. 
45% of patients in this relatively healthy HIV+ population were discovered to have atypical squamous cells or worse on 
entry into screening, and 20% of patients were ultimately shown on high resolution anoscopic biopsy histology to harbor 
high grade squamous intraepithelial lesions (AIN 2/3). Meaningful small scale anal cytology screening programs are 
possible with clinical and anoscopic collaborations. It seems possible that this simple and inexpensive test may prevent 
morbidity and mortality from HPV mediated anal carcinoma. 
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Introduction 
Studies of screening for anal dysplasia and 
carcinoma in human immunodeficiency virus (HIV) 
infected patients are increasingly appearing in the 
pathology literature. As an historical comparison, 
exfoliative cytology of the female genital tract 
(cervix and vagina) has been employed as a routine 
cancer screening test in North America for decades. 
This testing is now standard of care and has resulted 
in a significant diminution in the number of invasive 
cervical squamous carcinomas through early 
detection and subsequent management of precursor 
lesions. Prior to implementation of broad scale 
screening, cervical cancer was the number one 
cause of cancer mortality for women in the United 
States. Today, invasive cervical cancers are less 
commonly encountered, and this disease now falls 
outside of the “top ten” most frequently diagnosed 
and most commonly fatal malignancies for women
 
[1]. It is well known that nearly all cervical cancers 
are HPV mediated
 
[2, 3]. As the incidence and 
frequency of death from invasive cervical cancer 
has decreased, the incidence and frequency of death 
from anal cancer (another HPV mediated condition) 
has increased for both men and women
 
[4, 5]. Anal 
cancer precursors (like cervicovaginal dysplasias) 
are often asymptomatic, and because population 
based screening for anal neoplasia is not practiced, 
it is not uncommon for persons with HPV mediated 
anal disease to be diagnosed with mass lesions by 
digital anal exam or to present with symptoms such 
as bleeding. Certain specific populations may be 
predisposed to developing anal warts, dysplasias 
and carcinomas. Perhaps the most widely studied 
populations include HIV infected persons and men 
who have sex with men (whether HIV positive or 
not)
 
[6-11].
 
Availability of anal cytology screening 
is currently variable, and as anal dysplasia clinics 
open, some are reporting their findings
 
[12]. Most 
anal dysplasia screening programs are currently 
located in urban and highly populated geographies. 
Herein, we report our experiences with establishing 
an anal cytology screening program for HIV 
infected persons in Everett, Washington (a small 
Pacific Northwest community with a population of 
approximately 100,000 people). It is our hope that 
targeted screening of patient cohorts who are at 
highest risk of developing HPV mediated anal 
neoplasia may stem the tide of increasing disease 
incidence, ideally preventing both morbidity and 
mortality. 
Materials and Methods 
An electronic medical record retrieval for first time 
anal cytology screening tests (CellNetix Pathology 
and Laboratories, Everett, Washington, U.S.A.) was 
performed for the two year period 03/2011 through 
03/2013. All patients in this cohort were HIV+. All 
anal cytology samples were collected by one 
physician (S.A.D., Internal Medicine, HIV 
Specialist, American Academy of HIV Medicine) 
working in an outpatient clinic (The Everett Clinic, 
Harbour Pointe, U.S.A.). All samples were 
collected using Dacron swabs. The employed 
collection technique was based upon the 
instructional video Anal Pap Smear: A Simple, Fast 
& Easy Procedure HRSA Grant #6 H4AHA006002, 
2004, Johns Hopkins University School of 
Medicine, Infectious Disease Division. During the 
first seven months of the twenty-four month period, 
the samples were submitted in SurePath vials 
(Becton Dickinson Company). During the last 
seventeen months, the samples were submitted in 
ThinPrep vials (Hologic). Samples were processed 
per product guidelines. Cytomorphologic 
interpretation was based upon The Bethesda System 
for Reporting Cervical Cytology, Second Edition
 
[13]. Cytologic interpretations were performed by 
five board certified anatomic pathologist, some but 
not all of whom were board certified in 
cytopathology (“non-specialty” sign out). HPV 
DNA testing was not performed. Results of the 
retrieval were entered into a spread sheet for data 
organization and were correlated with a review of 
the electronic clinical / laboratory medical records 
of each of the identified patients. Data points 
gathered for spread sheet entry for each patient 
included age at time of cytology sample collection, 
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gender, HIV viral load (measured within preceding 
six months), CD4+ cell count (measured within 
preceding six months), documentation of current 
use of highly active antiretroviral therapy (HAART), 
and cytologic interpretation. All patients interpreted 
to have squamous intraepithelial lesions on cytology 
were referred to high resolution anoscopy. Most 
patients with atypical squamous cells were also 
referred to anoscopy, including all of those with 
atypical squamous cells cannot exclude high grade 
squamous intraepithelial lesion. Follow up 
information (12/2013, with time frames ranging 
from a minimum of 9 months to a maximum of 33 
months) was also recorded in spread sheet columns. 
Follow up data points included all subsequently 
available cytology or histology interpretations and 
corresponding chronologic intervals from the time 
of initial entry into the screening program. 
Institutional review board (IRB) approval for this 
retrospective project was sought and granted by 
Western IRB, Olympia, WA, letter dated 
08/30/2013. 
Results 
The anatomic pathology laboratory information 
system data retrieval identified 138 patients who 
underwent first-time anal cytology testing in the 
initial two years of the screening program at The 
Everett Clinic. The majority of patients were male 
(60%), and all patients were adults. Patient ages 
ranged from 20 to 72 years with a mean age of 44 
years.  (See Table 1 for demographic data). The 
majority (88%) of patients was receiving 
combination antiretroviral therapy at the time of 
anal cytology screening, and the majority of patients 
(75%) had viral loads that were undetectable by 
polymerase chain reaction testing. The mean CD4+ 
cell count was 595 cells/uL.
   
Table 1 Demographics 
Number of patients for first time anal cytology screening 138 
     Male 83 (60%) 
     Female 55 (40%) 
     Youngest age (years) 20 
     Oldest age (years) 72 
     Mean age (years) 44 
     Lowest absolute CD4+ cell count (cells/uL) 86 
     Highest absolute CD4+ cell count (cells/uL) 1253 
     Mean CD4+ cell count (cells/uL) 595 
     Lowest viral load (copies / ml) 0 (75%) 
     Highest viral load (copies / ml) 148,000 
     Mean viral load (copies / ml) 3,105 
     Currently on HAART 121 (88%) 
     Currently not on HAART 17 (12%) 
Number of patients with lesional (ASC & above) anal cytology 62 (45%) 
     Number of lesional patients with no follow up 21 (34%) 
     Number of lesional patients with cytology follow up 21 (34%) 
     Number of lesional patients with biopsy follow up 20 (32%) 
HAART = highly active antiretroviral therapy；ASC = atypical squamous cells 
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Of the 138 patients who underwent anal cytology 
screening, 62 (45%) were identified with abnormal 
squamous epithelial findings. (See Table 2 for 
cytology interpretations and subsequent biopsy 
follow up results). Thirty patients (22%) were 
interpreted to have atypical squamous cells of 
undetermined significance (ASC-US). Three 
patients (2%) were interpreted to have atypical 
squamous cells, cannot exclude high grade 
squamous intraepithelial lesion (ASC-H).  
Twenty-six patients (19%) were interpreted to 
harbor a low grade squamous intraepithelial lesion 
(LSIL). Three patients (2%) were interpreted to 
have high grade squamous intraepithelial lesions 
(HSIL). No invasive carcinomas were identified. Of 
the patients with lesional (initial cytology of ASC 
and above) interpretations, 41 (66%) had either 
additional cytology or histology follow up. 
Histologic follow up was made possible through 
routine processing of high resolution anoscopic 
biopsies (performed by L.L.S and J.C.d.l.O). The 
majority of patients without follow up were those in 
the ASC-US category. The percentages of patients 
with HSIL [anal intraepithelial neoplasia (AIN) 2/3] 
on biopsy follow up were 100% for those patients 
with HSIL cytology, 67% for those patients with 
ASC-H cytology, 42% for those patients with LSIL 
cytology, and 3% for those with ASC-US cytology. 
 
Table 2 Initial Cytology and Biopsy Follow Up  
Initial Cytology Interpretation # (%) HSIL (AIN2/3) on Biopsy Follow Up, # (%) 
Unsatisfactory 1 (1%)   
NILM 75 (54%)   
ASC-US 30 (22%) 1 (3% of patients with ASC-US) 
ASC-H 3 (2%) 2 (67% of patients with ASC-H) 
LSIL 26 (19%) 11 (42% of patients with LSIL) 
HSIL 3 (2%) 3 (100% of patients with HSIL) 
Totals: 138 (100%) 27 (20% of all patients in study) 
NILM = negative for intraepithelial lesion / malignancy, ASC-US = atypical squamous cells of undetermined 
significance, ASC-H = atypical squamous cells cannot exclude high grade dysplasia, LSIL = low grade squamous 
intraepithelial lesion, HSIL = high grade squamous intraepithelial lesion, AIN = anal intraepithelial neoplasia. 
 
Discussion 
Contrary to the noted decreasing trends of 
preinvasive and invasive squamous tumors of the 
cervix and vagina, age-adjusted incidence rates for 
preinvasive and invasive squamous anal 
malignancies have significantly increased over the 
last several decades
 
[4].
 
The incidence of anal 
cancer is known to be elevated in HIV infected men 
who have sex with men compared to the general 
population, and anal HSIL has clear potential to 
progress to invasive disease in this group
 
[6, 11].
 
The goal of clinical management of patients with 
HPV mediated lesions of the lower anogenital tract 
should be to identify and treat patients with high 
grade precursor lesions (HSIL) to decrease the risk 
of developing invasive cancers
 
[14].
 
Some 
investigators have suggested that risk factor 
assessment and stratification in HIV infected 
patients may help to disentangle the influences of 
anal exposure to HPV, immunodeficiency, tobacco 
smoking, and combined antiretroviral therapy
 
[15, 
16].
 
Such stratification might allow for development 
of algorithms as to which subpopulations are in 
greatest need of anal cytology screening. No clear 
correlations between degree of dysplasia and CD4+ 
cell counts or measurable viral loads could be made 
in our study; however, our population is relatively 
well and our cohort number is low. The small 
sample size is a limiting factor in our study. Some 
authors suggest annual screening for all patients 
with HIV, and this is our preferred approach [7]. 
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One unique characteristic of the population in our 
current retrospective review is the percentage of 
female patients presenting for first time screening 
and follow up (40%). The female patients in this 
cohort acquired their HIV infections through 
heterosexual practices and/or through intravenous 
drug use. It is uncertain what percentage of these 
women engaged in heterosexual anal intercourse. 
More than 20% of U.S. women ages 20-39 reported 
having anal sex in the past year in a recent nationally 
representative probability sample study
 
[17]. While 
women represented 40% of the patients initially 
screened, they represented only 13% of the patients 
who were ultimately found to harbor high grade 
squamous intraepithelial lesions (AIN 2/3) on high 
resolution anoscopy with biopsy over the average of 
21 months of follow up time. (See Table 3 for HSIL 
follows up by gender). The comparatively large 
percentage of female patients with HIV in this study 
may be one explanation for the somewhat lower 
fractions of patients with abnormal cytology in 
comparison to other reports.  
 
Table 3 Follow Up HSIL by Gender 
 Undergoing Primary  Follow Up (9 to 33 Months) 
 Anal Cytology Screening of HSIL (AIN 2/3) by HRA Biopsy 
Men 83/138 (60%) 14/16 (87%) 
Women 55/138 (40%) 2/16 (13%) 
HSIL = high grade squamous intraepithelial lesion, AIN = anal intraepithelial neoplasia, HRA = high resolution 
anoscopy. 
 
Another finding from this retrospective review is 
that cytology appears to underestimate the grade of 
dysplasia when compared to results of 
corresponding anoscopically guided biopsy 
histology. The sensitivity and specificity of a single 
anal cytology specimen have been reported to be 
comparable with those for a single cervical cytology 
test; however, lesional severity appears more likely 
to be underestimated on anal collections. High 
resolution anoscopy with biopsy and histologic 
interpretation is most often viewed as the gold 
standard [6, 18-19]. In the current review, 42% of 
patients (mostly men) interpreted to have LSIL on 
screening cytology were subsequently found to have 
HSIL on biopsy follow up. This figure is more than 
four times higher than the 10% we see in our 
geographically identical general cervical screening 
program (for all women of all ages and all immune 
statuses). 
In our local pathology professional group 
cervicovaginal and anal cytology cases are 
interpreted by all of the anatomic pathologists 
(non-specialty sign out). In revisiting the cytology 
and histology slides from all of the patients initially 
classified as LSIL on cytology, at least three of these 
patient’s could have been originally cytologically 
interpreted as HSIL. This would have increased the 
number of HSIL patients from 3 (2%) to 6 (4%). 
(See Figures 1, 2 and 3 for a case example of a 
patient interpreted with LSIL whose follow up 
revealed HSIL and retrospective cytology review 
confirmed rare overlooked high grade cells in the 
original screening cytology). While it cannot be said 
with absolute certainty, it may be that assignment of 
anal cytology cases to a focused group of 
pathologists with cytopathology expertise might 
result in greater accuracy and reproducibility. The 
literature on this topic suggests moderate to good 
agreement between cytopathohlogists evaluating 
anal cytology specimens from HIV positive men 
who have sex with men
 
[20].
 
A recent College of 
American Pathologists Interlaboratory Comparison 
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Program in Nongynecologic Cytology showed poor 
performance on anal cytology, especially in regard 
to the correct identification of HSIL, and indicated a 
need for continued education about anal cytology
 
[21].
   
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 Koilocytes identified in initial anal screening cytology from a 57 year-old, HIV+, male patient.  Anal 
cytology interpreted as LSIL (low grade squamous intraepithelial lesion).  Papanicolaou stain, 630X. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 Moderate to severe squamous dysplasia (anal intraepithelial lesion [AIN 2/3], high grade squamous 
intraepithelial lesion [HSIL]) in a histologically processed high resolution anoscopic biopsy from a 57 year-old, HIV+, 
male (same patient as Figure 1) whose screening cytology was originally interpreted as low grade squamous 
intraepithelial lesion (LSIL). Hematoxylin and eosin, 400X. 
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Figure 3 Rare cells of high grade squamous intraepithelial lesion (HSIL) in a 57 year-old, HIV+, male patient (same 
patient as in Figures 1 and 2) were identified on retrospective review for cyto-histologic correlation.  Papanicolaou 
stain, 630X. 
 
Currently, there are no national guidelines or 
organizationally approved recommendations for 
anal cytology screening of the general public. This 
lack of published guidelines for the general public 
results in many “unanswered” questions about 
which patients should be screened and at what 
screening intervals testing should be performed.  
Recent primary care guidelines from the Infectious 
Diseases Society of America (IDSA) for the specific 
management of persons infected with HIV provide a 
“weak recommendation based upon moderately 
quality evidence” that men who have sex with men, 
women with a history of receptive anal intercourse 
or abnormal cervical Pap tests, and all HIV infected 
individuals with genital warts should have an anal 
Pap test
 
[22]. With these new HIV related guidelines, 
there seems likely to be little argument that persons 
living with HIV and men who have sex with men 
may benefit from anal screening, and some authors 
suggest that patients in these categories who are 
screened and are interpreted to have atypical 
squamous cells (ASC) or above should be referred 
to high resolution endoscopy
 
[18]. In our practice in 
Everett, Washington, following this paradigm 
would result in a 45% anoscopy referral rate. It is 
important to remember that screening for 
screening’s sake alone is of no value, and patients 
who are discovered to have ASC or worse on 
cytology need to be examined by a well trained 
anoscopist. In establishing our program in Everett, 
we were limited in that no such person exists in our 
community. We do have the good fortune of being 
located within 40 miles of two high quality clinician 
anoscopists, and patients with abnormal findings are 
triaged to these providers in the Seattle metropolitan 
area for anoscopy with biopsy and appropriate 
follow up. In communities without high resolution 
anoscopy services, it is of paramount importance to 
establish clinical connections with a referral 
anoscopist prior to starting a screening service. 
Because the prevalence of anal HPV infection in 
HIV infected men is high (more than half of patients 
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in many studies), we chose not to reflex atypical 
cytology results to HPV DNA testing in designing 
our triage approach [23-27]. There is literature to 
suggest that commercially available DNA tests are 
valid for use in liquid based anal cytology samples
 
[28].
 
It is possible that HPV DNA testing might 
have utility in centers where anal cytology 
screening is performed on patient populations other 
than men who have sex with men and those with 
HIV. Other populations in which anal cytology 
screening might be considered are patients who are 
solid organ transplant recipients and well 
(non-immunocompromised women) who are 
known to have high grade squamous intraepithelial 
neoplasia (HSIL) of the cervix [29,30]. In those 
populations, reflex HPV DNA testing may be 
relevant. It seems possible that if patients were HPV 
DNA tested and found to be negative for high risk 
infections, they might be candidates for vaccination. 
There is some literature to suggest that combined 
high resolution anoscopy and anal cytology may be 
cost effective surveillance strategies after treatment 
for HSIL in HIV infected men
 
[31]. Broad scale 
outcomes studies that systematically assess the 
efficacy of anal cancer screening programs in 
reducing the incidence and morbidity and mortality 
of invasive anal cancers are needed
 
[32]. 
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